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Editorial
Bronchoalveolar Lavage (BAL) was initially used as a research tool, after being introduced by Reynolds and New-
ball in 19741.
Since then, the technique has prompted numerous studies, scientific and clinical, resulting in a wealth of  publica-
tions, also reflected in several international reports.
The first European Report on BAL, which discussed technical aspects of  the handling and clinical use of  speci-
mens obtained using this method, was published in 19892. It was revised in 19903, after the foundation of  the
European Society of  Pneumology Task Group on BAL and again in 19924. Its most recent publication, an exclu-
sive issue of  the European Respiratory Review of  July 19995 devoted to a study of  the non-cellular components of
BAL, also made further recommendations for the standardization of  the technique, the result of  the combined
efforts of  49 authors from 15 different countries and 21 guest reviewers.
The clinical applications of  BAL are actually very broad and in two recent expert statements on Interstitial Lung
Disease (ILD), BAL was included in the diagnostic setting in the absence of  morphologic confirmation: in Sarcoi-
dosis, in the appropriate clinical and laboratory context, the information of  a lymphocytic alveolitis with a CD4/
CD8 ratio higher than 3.5, without biopsy, could be sufficient to support the diagnosis6 and in Idiopathic Pulmo-
nary Fibrosis, BAL (and transbronchial lung biopsy) is one of  the major criteria in its diagnosis in the absence of
lung biopsy, namely showing no other identifiable condition as cause of  disease7.
The perspectives are also getting broader, not only with the computerized mathematical analysis of  logistic regres-
sion resorting to diverse variables related to BAL and other data of  the population under study as a method of
high positive accuracy in the differential diagnosis of  the more prevalent pulmonary interstitial conditions – sar-
coidosis, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis8 –, but also with the field of  proteomics,
analysing gene products and proteic content of  BAL in various diseases, potentially useful to identify, in the future,
markers of  diagnosis, in follow-up and to support new therapies9.
These are good reasons for the honour of  having been Chairman of  the 10th International Conference on BAL,
held in Coimbra in June 2006, and we wish to thank the Chairman of  the “International BAL Group”, Ulrich
Costabel, and the Chairman of  ERS Group 1.5, “Diffuse Parenchymal Lung Disease”, Marjolein Drent, for their
active cooperation.
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From this meeting, the first scientific event endorsed by the ERS in Portugal, we would like to emphasize some
other relevant aspects, such as the participation of  delegates from 20 countries, the significant number of  abstracts
(55) from 16 different countries, the quality of  the Conferences, Panels and Symposia (where we heard about the
most recent data of  the international trial on Anti-TNF in ILD), the Workshop on Induced Sputum the day after
the meeting and also the significant participation of  Portuguese pneumology.
Finally, we are also grateful to the Portuguese Society of  Pneumology, for publishing this issue of  the “Revista
Portuguesa de Pneumologia” with part of  the proceedings from the Conference and to GlaxoSmithKline for the
support provided.
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